Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cream could ease painful skin bumps for HS patients

NCT ID NCT06959225

Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jul 29, 2026 · Updated 3 times

Summary

This study tests a cream called ruxolitinib for people with mild to moderate hidradenitis suppurativa (HS), a chronic skin condition causing painful bumps and tunnels. About 550 participants will apply the cream or a placebo twice daily for several weeks. The main goal is to see if the cream reduces the number of inflamed bumps by at least 75% and prevents flares.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ruxolitinib cream
What this could lead to
If it works, this could offer a new topical treatment option for people with mild to moderate hidradenitis suppurativa, reducing painful bumps and flares without needing oral antibiotics.
What could go wrong
This is a Phase 3 trial, but results are not yet known. The cream may not work better than a placebo, and side effects like skin irritation are possible. It is not a cure, and ongoing management may still be needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

580 people

The number who actually took part.

Started

Jun 2025

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of HS for at least 6 months prior to screening visit. * Mild to moderate HS (Hurley I or II) with the following at both screening and baseline visits: * A total AN count of at least 4, with no draining tunnels AND * Affecting at least 2 distinct anatomical areas * Agreement to NOT use topical and systemic antibiotics for treatment of HS during the vehicle-controlled period. * Agreement to NOT use topical antiseptics, including washes and leave-on products on the areas affected by HS lesions during the vehicle-controlled period and Weeks 16 to 20 of the extension period. * Further inclusion criteria apply. Exclusion Criteria: * Body surface areas to be treated exceed 20% BSA at screening or baseline * Presence of draining tunnels at screening or baseline. * Medical history including current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator. * Laboratory values outside of the protocol-defined criteria. * Pregnant or lactating participants, or those considering pregnancy during the period of their study participation. * Further exclusion criteria apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hidradenitis suppurativa are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hidradenitis suppurativa skin disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hidradenitis suppurativa

Contacts and locations

Locations

  • Investigative Site BG002

    Sofia, 01407, Bulgaria

  • Investigative Site BG003

    Sofia, 01463, Bulgaria

  • Investigative Site CA001

    Richmond Hill, Ontario, L4B 1L1, Canada

  • Investigative Site CA002

    Peterborough, Ontario, K9J 5K2, Canada

  • Investigative Site CA003

    Calgary, Alberta, T3E 0B2, Canada

  • Investigative Site CA004

    Calgary, Alberta, T2J 7E1, Canada

  • Investigative Site CA005

    Toronto, Ontario, M4E 1R7, Canada

  • Investigative Site CA006

    Waterloo, Ontario, N2J 1C4, Canada

  • Investigative Site CA007

    Toronto, Ontario, M3B 0A7, Canada

  • Investigative Site CA008

    Sherbrooke, Quebec, J1G 1X9, Canada

  • Investigative Site CA009

    Ottawa, Ontario, K1K 4L2, Canada

  • Investigative Site DE001

    Dresden, 01307, Germany

  • Investigative Site DE002

    Bochum, 44791, Germany

  • Investigative Site DE003

    Erlangen, 91054, Germany

  • Investigative Site DE004

    Darmstadt, 64283, Germany

  • Investigative Site DE005

    Berlin, 13595, Germany

  • Investigative Site DE006

    Berlin, 10117, Germany

  • Investigative Site DE007

    Hamburg, 20246, Germany

  • Investigative Site DE008

    Lübeck, 23538, Germany

  • Investigative Site ES001

    Madrid, 28009, Spain

  • Investigative Site ES002

    Madrid, 28040, Spain

  • Investigative Site ES003

    Barcelona, 08003, Spain

  • Investigative Site ES004

    Alicante, 03010, Spain

  • Investigative Site ES005

    Badalona, 08916, Spain

  • Investigative Site FR001

    Paris, 75010, France

  • Investigative Site FR002

    Bordeaux, 33000, France

  • Investigative Site FR003

    Nice, 06200, France

  • Investigative Site FR004

    Nantes, 44093, France

  • Investigative Site FR005

    Brest, 29609, France

  • Investigative Site IT001

    Catania, 95123, Italy

  • Investigative Site IT002

    Rozzano, 20089, Italy

  • Investigative Site IT003

    Milan, 20122, Italy

  • Investigative Site IT004

    Roma, 00144, Italy

  • Investigative Site IT005

    Cona, 44124, Italy

  • Investigative Site IT006

    Roma, 00137, Italy

  • Investigative Site IT007

    Naples, 80131, Italy

  • Investigative Site IT008

    Torino, 10126, Italy

  • Investigative Site IT009

    Florence, 50122, Italy

  • Investigative Site PL001

    Warsaw, 02-962, Poland

  • Investigative Site PL002

    Lodz, 90-436, Poland

  • Investigative Site PL003

    Torun, 87-100, Poland

  • Investigative Site PL004

    Wroclaw, 54-239, Poland

  • Investigative Site US001

    Bowling Green, Kentucky, 42104, United States

  • Investigative Site US002

    Fayetteville, Arkansas, 72703, United States

  • Investigative Site US003

    Boston, Massachusetts, 02115, United States

  • Investigative Site US004

    Laguna Niguel, California, 92677, United States

  • Investigative Site US006

    Minneapolis, Minnesota, 55455, United States

  • Investigative Site US007

    Los Angeles, California, 90033, United States

  • Investigative Site US008

    Columbus, Ohio, 43230, United States

  • Investigative Site US010

    Quincy, Massachusetts, 02169, United States

  • Investigative Site US011

    San Antonio, Texas, 78213, United States

  • Investigative Site US012

    Plano, Texas, 75025, United States

  • Investigative Site US013

    San Diego, California, 92103, United States

  • Investigative Site US014

    Chapel Hill, North Carolina, 27516, United States

  • Investigative Site US015

    Bexley, Ohio, 43209, United States

  • Investigative Site US016

    Miami, Florida, 33142, United States

  • Investigative Site US017

    New York, New York, 10023, United States

  • Investigative Site US018

    New York, New York, 10003, United States

  • Investigative Site US019

    Marietta, Georgia, 30060, United States

  • Investigative Site US020

    Phoenix, Arizona, 85008, United States

  • Investigative Site US021

    New Brighton, Minnesota, 55112, United States

  • Investigative Site US022

    Louisville, Kentucky, 40241, United States

  • Investigative Site US023

    Rochester, New York, 14623, United States

  • Investigative Site US024

    Charleston, South Carolina, 29425, United States

  • Investigative Site US025

    Fargo, North Dakota, 58103, United States

  • Investigative Site US026

    Chicago, Illinois, 60657, United States

  • Investigative Site US027

    Sanford, Florida, 32771, United States

  • Investigative Site US028

    Fort Myers, Florida, 33912, United States

  • Investigative Site US029

    Tampa, Florida, 33609, United States

  • Investigative Site US030

    Boston, Massachusetts, 02215, United States

  • Investigative Site US031

    Mason, Ohio, 45040, United States

  • Investigative Site US032

    Frisco, Texas, 75033, United States

  • Investigative Site US033

    Scottsdale, Arizona, 85259, United States

  • Investigative Site US034

    New City, New York, 10956, United States

  • Investigative Site US035

    El Paso, Texas, 79902, United States

  • Investigative Site US036

    Saint Joseph, Missouri, 64506, United States

  • Investigative Site US037

    Murray, Utah, 84107, United States

  • Investigative Site US038

    San Diego, California, 92121, United States

  • Investigative Site US039

    Ogden, Utah, 84405, United States

  • Investigative Site US040

    Layton, Utah, 84041, United States

  • Investigative Site US041

    Myrtle Beach, South Carolina, 29788, United States

  • Investigative Site US043

    Danville, Pennsylvania, 17822, United States

  • Investigative Site US044

    Cincinnati, Ohio, 45219, United States

  • Investigative Site US045

    Boynton Beach, Florida, 33437, United States

  • Investigative Site US046

    Glenn Dale, Maryland, 20769, United States

  • Investigative Site US047

    Nashville, Tennessee, 37215, United States

  • Investigative Site US048

    Oklahoma City, Oklahoma, 73118, United States

  • Investigative Site US049

    Clarksville, Indiana, 47129, United States

  • Investigative Site US050

    Baton Rouge, Louisiana, 70809, United States

  • Investigative Site US051

    Novi, Michigan, 48377, United States

  • Investigative Site US052

    West Lafayette, Indiana, 47906, United States

  • Investigative Site US053

    Atlanta, Georgia, 30331, United States

  • Investigative Site US054

    Tempe, Arizona, 85282, United States

  • Investigative Site US055

    Brea, California, 92821, United States

  • Investigative Site US056

    Philadelphia, Pennsylvania, 19107, United States

  • Investigative Site US057

    Sweetwater, Florida, 33172, United States

  • Investigative Site US058

    Seattle, Washington, 98195, United States

  • Investigative Site US059

    Aurora, Colorado, 80045, United States

  • Investigative Site US060

    San Diego, California, 92120, United States

  • Investigative Site US061

    Atlanta, Georgia, 30322, United States

  • Investigative Site US062

    Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.